CompletedPhase 3

Mycophenolate Mofetil in Patients With Progressive Idiopathic Membranous Nephropathy

South Korea43 participantsStarted 2011-03

Plain-language summary

Cyclosporin decreases proteinuria and improve renal function in patients with idiopathic membranous nephropathy, but has a risk of side effects such as nephrotoxicity. The investigators plan to the study to evaluate whether mycophenolate mofetil (MMF) could be a reasonable alternative with fewer side effect.

Who can participate

Age range18 Years

SexALL

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

Inclusion criteria

✓. Patients with idiopathic membranous nephropathy
✓. The duration of disease is less than twelve months
✓. Patients with persistent proteinuria more than 8 grams per day
✓. Patients who provided informed consent
✓. The cases that satisfy more than three of following items even if proteinuria is less than 8 grams per day:

Exclusion criteria

✕. Severe digestive organ disease
✕. Allergy history to clinical trial medication and acute or chronic allergy for 4 weeks recently.
✕. Clinical history of treatment with other immunosuppressive medication
✕. Probability of pregnancy, breast feeding woman
✕. Uncontrolled hypertension (more than 160/100mmHg)
✕. Uncontrolled systemic disease
✕. Drug addiction or alcoholics within 6 months
✕. eGFR is less than 30ml/min at screening

What they're measuring

Percentage of Complete Remission

Timeframe: at 48 week after treatment

Percentage of Partial Remission

Timeframe: at 48 week after treatment

Trial details

NCT IDNCT01282073

SponsorKyungpook National University Hospital

Sponsor typeOTHER

Study typeINTERVENTIONAL

Primary completion2016-05

Results submitted2025-08-10

View on ClinicalTrials.gov More Glomerulonephritis, Membranous trials